Vote Scores

Home / Companies / Hikma Pharmaceuticals Plc / 24 Apr 2025

Meeting · year to 30 June 2025139 filers reporting

Hikma Pharmaceuticals Plc: meeting of 24 Apr 2025

Votes reported on Form N-PX, item by item

139 Form N-PX filers reported votes at the Hikma Pharmaceuticals Plc meeting of 24 Apr 2025. Their records fall into 8 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

10 nominees; 98.9% of reported votes for; 14 filers withheld from or voted against at least one nominee.

2,370 vote records from 122 filers. 0 of the 122 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management122 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

86 vote records from 33 filers. 0 of the 32 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

97.0% for0.0% against3.0% other0.0% against management33 filers100.0% for0.0% against0.0% against management15,346,945 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

474 vote records from 122 filers. 0 of the 122 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management122 filers100.0% for0.0% against0.0% against management37,656,418 reported shares
4

SHAREHOLDER RIGHTS AND DEFENSESIssuer

SHAREHOLDER RIGHTS AND DEFENSES: management items

Management items in this category are shown together; filers word and number them differently.

492 vote records from 122 filers. 0 of the 122 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management122 filers100.0% for0.0% against0.0% against management40,645,243 reported shares, counted once per item in this group
5

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

1,185 vote records from 122 filers. 0 of the 122 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management122 filers97.9% for2.1% against2.1% against management94,141,045 reported shares, counted once per item in this group
6

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

201 vote records from 106 filers. 0 of the 106 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management106 filers100.0% for0.0% against0.0% against management14,593,977 reported shares, counted once per item in this group
7

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

435 vote records from 122 filers. 0 of the 122 filers that marked the item either way voted against management.

91.0% for0.0% against9.0% other0.0% against management122 filers99.1% for0.9% against0.9% against management33,638,145 reported shares, counted once per item in this group
8

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

17 vote records from 11 filers. 0 of the 11 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management11 filers100.0% for0.0% against0.0% against management965,416 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForNo reportFor
BlackRock and iSharesForForFor
FidelityForNo reportFor
DimensionalForNo reportFor
State Street and SPDRForNo reportFor
American CenturyForNo reportFor
Franklin TempletonForNo reportFor
InvescoForNo reportFor
EquitableForNo reportFor
Charles SchwabForNo reportFor
Nuveen and TIAAForNo reportFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertForNo reportFor
J.P. MorganForForFor
Goldman SachsForNo reportFor
WisdomTreeForNo reportFor
PGIM and PrudentialForNo reportFor
Jackson National fundsForForFor
Northern Trust and FlexSharesForForFor
SEIForNo reportFor
T. Rowe PriceForNo reportFor
ThriventForNo reportFor
Lincoln FinancialForNo reportFor
VoyaForNo reportFor
First TrustForNo reportFor
Russell InvestmentsForNo reportFor
NationwideForNo reportFor
Victory CapitalForNo reportFor
Brighthouse FundsForNo reportFor
Columbia ThreadneedleForNo reportFor
BNY MellonForNo reportFor
PrincipalForNo reportFor
TransamericaForNo reportFor
AllianceBernsteinForNo reportFor
Hartford FundsForNo reportFor
PIMCOForNo reportFor
Harbor FundsForForFor
American BeaconForNo reportFor
Lord AbbettForNo reportFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Hikma Pharmaceuticals Plc meeting?

139 Form N-PX filers reported votes at the meeting of 24 Apr 2025. On say-on-pay, 0 of 32 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Hikma Pharmaceuticals Plc on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Hikma Pharmaceuticals Plc

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Hikma Pharmaceuticals Plc with a meeting date within three days of 24 Apr 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.